Clinical Trials Logo

Dlbcl-Ci clinical trials

View clinical trials related to Dlbcl-Ci.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04512716 Recruiting - Clinical trials for Diffuse Large B-cell Lymphoma

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Start date: February 2, 2021
Phase: Early Phase 1
Study type: Interventional

This is a pilot study; patients will receive 131-I apamistamab prior to CAR T-cell infusion in order to determine the maximum tolerated dose of 131-I apamistamab is exceeded at 75 mCi, and if so, to assess the safety of a step-down dose of 50 mCi.